Document is current
Any future updates will be listed below
-
Authors
Leipold, Alexander M. http://orcid.org/0000-0002-9471-3276
Werner, Rudolf A.
Düll, Johannes
Jung, Pius
John, Mara
Stanojkovska, Emilia
Zhou, Xiang
Hornburger, Hannah
Ruckdeschel, Anna
Dietrich, Oliver
Imdahl, Fabian
Krammer, Tobias
Knop, Stefan
Rosenwald, Andreas
Buck, Andreas
Sander, Leif Erik
Einsele, Hermann http://orcid.org/0000-0002-7680-0819
Kortüm, K. Martin http://orcid.org/0000-0002-7011-0286
Saliba, Antoine-Emmanuel http://orcid.org/0000-0001-8539-2784
Rasche, Leo http://orcid.org/0000-0002-9536-9649
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (MSNZ, MSNZ)
Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (TissueNet)
- License Information
-
More Information
Article History
Received: 28 November 2022
Revised: 12 January 2023
Accepted: 17 January 2023
First Online: 31 January 2023
Competing interests
: LR has participated in scientific advisory boards for Janssen, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Sanofi, has received research support from Skyline Dx, and has received honoraria from Janssen, Celgene/Bristol-Myers Squibb, Amgen, Pfizer, and Sanofi. HE has participated in scientific advisory boards for Janssen, Celgene/Bristol-Myers Squibb, Amgen, Novartis, and Takeda, has received research support from Janssen, Celgene/Bristol-Myers Squibb, Amgen, and Novartis, and has received honoraria from Janssen, Celgene/Bristol-Myers Squibb, Amgen, Novartis, and Takeda. The other authors declare no competing interests.
: The patient gave written informed consent for scientific evaluations. The study was approved by the internal review board of the University of Würzburg (reference # 8/21) and adhered to the tenets of the Declaration of Helsinki of 2008.
